| abstract |
A recombinant lentiviral vector comprising a first therapeutic gene that reduces or inhibits ocular angiogenesis for use in the treatment of age-related macular degeneration in an individual, in which the first therapeutic gene is selected from the group consisting of endostatin, angiostatin, endostatin XVIII, endostatin XV, the C-terminal hemopexin domain of the metalloproteinase-2 matrix, the human deplasminogen kringle 5 domain, the interferon-gamma (Mig) -induced monokine, the interferon-alpha-inducible protein (IP10), soluble FLT-1 (fms-like tyrosine kinase 1 receptor), and the kinase insertion domain receptor (KDR). |